BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $239,000.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total value of $239,000.00. Following the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at approximately $7,593,412.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

BioLife Solutions Trading Up 0.2 %

Shares of BLFS stock opened at $25.77 on Friday. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.19 billion, a P/E ratio of -18.15 and a beta of 1.87. The stock has a 50 day simple moving average of $24.17 and a 200 day simple moving average of $20.91. BioLife Solutions, Inc. has a 1 year low of $8.92 and a 1 year high of $26.73.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. The business had revenue of $28.33 million during the quarter, compared to analysts’ expectations of $23.80 million. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. On average, research analysts predict that BioLife Solutions, Inc. will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors have recently made changes to their positions in the stock. Meros Investment Management LP boosted its stake in shares of BioLife Solutions by 1.7% in the second quarter. Meros Investment Management LP now owns 399,803 shares of the medical equipment provider’s stock valued at $8,568,000 after buying an additional 6,586 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of BioLife Solutions by 5.8% in the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock valued at $296,000 after buying an additional 753 shares during the period. Squarepoint Ops LLC bought a new stake in shares of BioLife Solutions in the second quarter valued at approximately $1,041,000. Fred Alger Management LLC boosted its stake in shares of BioLife Solutions by 6.0% in the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after buying an additional 88,840 shares during the period. Finally, Marshall Wace LLP acquired a new position in BioLife Solutions during the second quarter valued at approximately $229,000. 93.24% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BLFS has been the subject of a number of research analyst reports. Northland Securities boosted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Craig Hallum boosted their price objective on BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, TD Cowen boosted their price objective on BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, July 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $26.20.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.